Figure 6

The effect of Cav-2 KO bone marrow cell co-injection on TAM subsets in LLC tumors. Freshly isolated bone marrow (BM) cells from WT vs. Cav-2 KO mice were co-injected s.c. with LLC (10⁶ cells) at 1:1 ratio in the lower back flanks of WT recipient mice as described in Methods. Tumors were extracted at day 8 and single cell suspensions were prepared and stained with fluorescence-conjugated antibodies for flow cytometry as described in Methods. (A) Gating strategy of MHC II^hi and MHC II^lo TAM subsets in LLC tumors from WT mice co-injected with WT BM (top panels) and Cav-2 KO BM (bottom panels). (B) Percentage of MHC II^hi TAM (left panel) and MHC II^lo TAM (central panel) within CD11b⁺F4/80⁺ cells  in LLC tumors as well as combined percentages of MHC II^hi TAM versus MHC II^lo TAM within CD11b⁺F4/80⁺ cells  (right panel). (C) Percentage of MHC II^hi TAM (left panel) and MHC II^lo TAM (central panel) among total cells in LLC tumors  as well as combined percentage of MHC II^hi TAM vs. MHC II^lo TAM among total cells in tumors  (right panel) from WT mice co-injected with WT vs. Cav-2 KO BM. Data are from distinct samples and presented as the mean ± SEM. *p < 0.05, **p < 0.01 compared with mice co-injected with WT BM by unpaired t-test; n = 4.